Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025
Download Free Sample Buy Now
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025

By Drug Class (Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes), By Indication (Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections), By MRSA Type (Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA) ), By Route of Administration (Oral Administration, Parenteral Administration), By End User (Hospitals and Clinics, Research and Academic Institutes, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

• Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market size has reached to $2.35 billion in 2024

• Expected to grow to $3.03 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%

• Growth Driver: Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections

• Market Trend: Launch Of First Generic Version Of Combination Therapy For Helicobacter Pylori

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?

Methicillin-resistant Staphylococcus aureus (MRSA) drugs refer to a group of drugs used to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other common antibiotics. These drugs are specifically chosen to target and kill MRSA bacteria or inhibit their growth. MRSA is a source of staph infections that is challenging to treat due to antibiotic resistance.

The main types of methicillin-resistant Staphylococcus aureus (MRSA) drugs are lipopeptides, oxazolidinones, cephalosporins, tetracyclines, folate antagonists, lipoglycopeptides, and others. Lipopeptides are a class of antibiotics that contain both lipid and peptide components and exhibit therapeutic intervention by disrupting the bacterial cell membrane, leading to membrane depolarization and inhibition of cell wall synthesis. Various types of indications include skin infections, bone and joint infections, bacteremia, and animal infections. The several types of methicillin-resistant Staphylococcus aureus (MRSA) involved are hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). These drugs are administered by oral and parenteral routes of administration and are used by various end users, such as hospitals and clinics, research and academic institutes, and others.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size 2025 And Growth Rate?

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size has grown steadily in recent years. It will grow from$2.35 billion in 2024 to $2.44 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to antibiotic resistance concerns, hospital-acquired infections, surgical procedures, global increase in MRSA cases, high mortality rates

What Is The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Growth Forecast?

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to continued antibiotic resistance challenges, advancements in MRSA diagnostics, global healthcare-associated infections, preventive measures in surgery, rising community-acquired MRSA cases. Major trends in the forecast period include exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, focus on pediatric-specific formulations, global health initiatives to combat antibiotic resistance.

The forecast of 5.6% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. hospitals by increasing the cost of linezolid IV formulations and rapid methicillin-resistant staphylococcus aureus polymerase chain reaction testing kits sourced from India and Germany, thereby prolonging infection control measures and elevating antimicrobial stewardship program costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmented?

1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes

2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections

3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)

4) By Route of Administration: Oral Administration, Parenteral Administration

5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users

Subsegments:

1) By Lipopeptides: Daptomycin

2) By Oxazolidinones: Linezolid, Tedizolid

3) By Cephalosporin: Ceftaroline

4) By Tetracycline: Minocycline, Doxycycline

5) By Folate Antagonist: Trimethoprim Or Sulfamethoxazole

6) By Lipoglycopeptide: Telavancin, Dalbavancin, Oritavancin

7) By Other Drug Classes: vancomycin, Clindamycin, Quinupristin Or Dalfopristin

What Is Driving The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market? Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections

Rising Hospital Acquired Infections (HAIs) expected to boost the growth of the methicillin-resistant Staphylococcus aureus drugs market going forward. Hospital-acquired infections (HAIs) are infections that patients develop while receiving treatment in a healthcare facility, occurring 48 hours or more after admission. Hospital-acquired infections (HAIs) are attributed to factors such as contaminated medical equipment, poor hand hygiene among healthcare staff, overuse of antibiotics, prolonged hospital stays, and weakened immune systems of patients. Methicillin-resistant Staphylococcus aureus (MRSA) drugs help treat hospital-acquired infections by targeting and eliminating MRSA strains that are resistant to standard antibiotics, reducing the spread and severity of these infections in healthcare settings. For instance, in 2023, the World Health Organization, a Switzerland-based Intergovernmental organization, reported that an estimated 136 million cases of health care-associated antibiotic-resistant infections occur worldwide every year. Therefore, the increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is driving the growth of the methicillin-resistant Staphylococcus aureus drug market.

What Is Driving The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market? Growing Elderly Population Boost The Market

An increase in the elderly population is expected to boost the growth of the methicillin-resistant Staphylococcus aureus (MRSA) drugs market going forward. The elderly population is defined as people 65 years of age and older. The total number of elderly and young people expressed as a percentage of the total population is used to calculate the proportion of the dependent population. Senior citizens are more vulnerable to infections, including MRSA, as their immune systems have been compromised by aging. Bacterial infections, such as MRSA, are more common as people age because their immune systems become less effective at defending the body against injury. For instance, in October 2022, according to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or older. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Therefore, the increase in elderly population infections is driving the growth of the methicillin-resistant Staphylococcus aureus (MRSA) drugs industry.

Who Are The Major Players In The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?

Major companies operating in the methicillin-resistant staphylococcus aureus (MRSA) drugs market include Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AmpliPhi Biosciences Corporation, AstraZeneca plc, Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

What Are The Key Trends Of The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market? Launch Of First Generic Version Of Combination Therapy For Helicobacter Pylori

Product innovation is the key trend gaining popularity in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market. Major companies involved in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focused on innovating new products to improve their observation power and sustain their position in the market. For instance, in March 2023, Endo, a US-based biopharmaceutical firm, launched the first generic version of Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) capsules, offering a more affordable treatment option for patients suffering from Helicobacter pylori infections. This launch aims to enhance access to effective therapy for gastric ulcers while contributing to cost savings in healthcare, ensuring that more patients can receive the necessary treatment to manage their conditions effectively

What Are The Key Trends Of The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market? Innovative Once-Daily Dosing Solutions For Antibiotic Treatment

Major companies involved in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focused on once-daily dosing regimens to improve patient adherence to treatment, reduce the complexity of medication schedules, and enhance the overall effectiveness of therapies aimed at combating MRSA infections. Once-daily dosing regimens are medication administration schedules in which a drug is taken or administered just one time per day. For example, in August 2024, Sun Pharma, an India-based biotechnology company, launched Tedizolid Phosphate tablets 200 mg, which offers a convenient once-daily dosing option for patients with acute bacterial skin and skin structure infections, including those caused by MRSA, thereby supporting better treatment adherence and outcomes.

Need data on a specific region in this market?
Request Regional Data

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Merger And Acquisition: Brii Biosciences Expands Global Reach With Acquisition Of BRII-693 From Qpex Biopharma

In June 2023, Brii Biosciences, a China-based company, acquired Qpex Biopharma’s Exclusive Global Rights for BRII-693 for an undisclosed amount. The acquisition aims to strengthen its portfolio of innovative therapeutics targeting infectious diseases, particularly those caused by multidrug-resistant pathogens, enhancing its position in the global biopharmaceutical market and expanding its capacity to address critical unmet medical needs. Qpex Biopharma, a US-based Company manufactures Methicillin-resistant Staphylococcus aureus (MRSA) drugs

Regional Analysis For The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?

The methicillin-resistant Staphylococcus aureus (MRSA) drug market consists of sales of vancomycin, daptomycin, linezolid, ceftaroline, tedizolid, and clindamycin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Industry?

The methicillin-resistant staphylococcus aureus (mrsa) drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the methicillin-resistant staphylococcus aureus (mrsa) drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $2.44 billion
Revenue Forecast In 2034 $3.03 billion
Growth Rate CAGR of 5.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users Subsegments: 1) By Lipopeptides: Daptomycin
2) By Oxazolidinones: Linezolid, Tedizolid
3) By Cephalosporin: Ceftaroline
4) By Tetracycline: Minocycline, Doxycycline
5) By Folate Antagonist: Trimethoprim Or Sulfamethoxazole 6) By Lipoglycopeptide: Telavancin, Dalbavancin, Oritavancin 7) By Other Drug Classes: Vancomycin, Clindamycin, Quinupristin Or Dalfopristin
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AmpliPhi Biosciences Corporation, AstraZeneca plc, Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Characteristics

3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies

4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Growth Rate Analysis

5.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Total Addressable Market (TAM)

6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segmentation

6.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lipopeptides

Oxazolidinones

Cephalosporin

Tetracycline

Folate Antagonist

Lipoglycopeptide

Other Drug Classes

6.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Skin Infections

Bone and Joint Infections

Bacteremia

Animal Infections

6.3. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital-Acquired (HA-MRSA)

Community-Acquired (CA-MRSA)

6.4. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral Administration

Parenteral Administration

6.5. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals and Clinics

Research and Academic Institutes

Other End-Users

6.6. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipopeptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Daptomycin

6.7. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Linezolid

Tedizolid

6.8. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ceftaroline

6.9. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Minocycline

Doxycycline

6.10. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Folate Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Trimethoprim Or Sulfamethoxazole

6.11. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipoglycopeptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Telavancin

Dalbavancin

Oritavancin

6.12. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Vancomycin

Clindamycin

Quinupristin Or Dalfopristin

7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Regional And Country Analysis

7.1. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

8.1. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

9.1. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

9.2. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

10.1. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

11.1. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

11.2. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

12.1. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

13.1. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

14.1. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

14.2. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

15.1. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

15.2. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

16.1. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

17.1. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

18.1. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

19.1. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

20.1. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

21.1. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

21.2. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

22.1. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

23.1. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

23.2. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

24.1. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

24.2. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

25.1. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

25.2. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

26.1. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

26.2. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

27.1. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

28.1. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

28.2. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

29.1. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Overview

29.2. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape And Company Profiles

30.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Landscape

30.2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Company Profiles

30.2.1. Basilea Pharmaceutica Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Theravance Biopharma Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis

31. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Other Major And Innovative Companies

31.1. Cumberland Pharmaceuticals Inc.

31.2. Debiopharm International S.A.

31.3. AbbVie Inc.

31.4. Innovation Pharmaceuticals Inc.

31.5. Melinta Therapeutics Inc.

31.6. Nabriva Therapeutics plc

31.7. Paratek Pharmaceuticals Inc.

31.8. Teva Pharmaceutical Industries Ltd.

31.9. AmpliPhi Biosciences Corporation

31.10. AstraZeneca plc

31.11. Meiji Seika Kaisha Ltd.

31.12. GlaxoSmithKline plc

31.13. Johnson & Johnson

31.14. Sanofi S.A.

31.15. Novartis

32. Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

34. Recent Developments In The Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

35. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market High Potential Countries, Segments and Strategies

35.1 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipopeptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Folate Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipoglycopeptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Asia-Pacific, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: China, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: India, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Japan, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Australia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Indonesia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: South Korea, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Western Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: UK, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Germany, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: France, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Italy, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Spain, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Eastern Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Russia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: North America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: USA, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Canada, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: South America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Brazil, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Middle East, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Africa, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 83: Basilea Pharmaceutica Ltd. Financial Performance
  • Table 84: Merck & Co Inc. Financial Performance
  • Table 85: Pfizer Inc. Financial Performance
  • Table 86: Theravance Biopharma Inc. Financial Performance
  • Table 87: Allergan plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipopeptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Oxazolidinones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Folate Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Lipoglycopeptide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Asia-Pacific, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: China, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: India, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Japan, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Australia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Indonesia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: South Korea, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Western Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: UK, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Germany, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: France, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Italy, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Spain, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Eastern Europe, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Russia, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: North America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: USA, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Canada, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: South America, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Brazil, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Middle East, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Africa, Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market, Segmentation By MRSA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 83: Basilea Pharmaceutica Ltd. Financial Performance
  • Figure 84: Merck & Co Inc. Financial Performance
  • Figure 85: Pfizer Inc. Financial Performance
  • Figure 86: Theravance Biopharma Inc. Financial Performance
  • Figure 87: Allergan plc Financial Performance

2025 Over-The-Counter (OTC) Diet Products Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Over-The-Counter (OTC) Diet Products Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Parathyroid Disease Treatment Market Revenue Outlook: Strategic Insights and Forecast to 2029

Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

Read More About Industry Forecast: PCSK9 Inhibitor Market to Generate $6.87 Billion Revenue by 2029

CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

Read More About CAGR of 5.4% Projected for Pediatric Asthma Treatment Market From 2025 to 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the MSI-H and DMMR Market with 2025 insights from The Business Research Company.

Anti-Infective Drugs Global Market Report 2022 – By Type (Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others...

View Report

Antibiotics Global Market Report 2025 – By Drug Class (Penicillin, Cephalosporin, Aminoglycosides, Tetracycline, Macrolides, Fluoroquinolones, Sulfonamides, Other Classes), By Spectrum Of Activity (Broad-spectrum Antibio...

View Report

Antibiotic Resistance Global Market Report 2025 – By Drug Class (Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones, Other Drug Classes), By Pathogen (Sta...

View Report

Multidrug Resistant Bacteria Global Market Report 2025 – By Disease (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin And Skin Structure...

View Report

Veterinary Antibiotics Global Market Report 2025 – By Product (Anti-parasitic, Anti-bacterial, Non-steroidal anti-inflammatory drug, Others), By End User (Farm Animals , Companion Animals), By Administration (Premixes, I...

View Report

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2025 – By Drug Class (Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes), By ...

View Report

Metformin Global Market Report 2025 – By Product Type (Standard-Release Tablets, Slow-Release Tablets), By Dosage Type (500MG, 750MG, 850MG, 1G), By End-user (Clinics, Hospitals, Homecare, Other End-Users) – Impact of Ta...

View Report

Anti-Infective Drugs Market - By Type (Antibiotics, Antivirals, Antifungals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classifi...

View Report

Frequently Asked Questions

Methicillin-resistant Staphylococcus aureus (MRSA) drugs refer to a group of drugs used to treat infections caused by the bacterium Staphylococcus aureus that are resistant to methicillin and other common antibiotics. These drugs are specifically chosen to target and kill MRSA bacteria or inhibit their growth. MRSA is a source of staph infections that is challenging to treat due to antibiotic resistance. For further insights on this market, request a sample here

The market major growth driver - Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections. For further insights on this market, request a sample here

The methicillin-resistant staphylococcus aureus (MRSA) drugs market size has grown steadily in recent years. It will grow from $2.35 billion in 2024 to $2.44 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to antibiotic resistance concerns, hospital-acquired infections, surgical procedures, global increase in MRSA cases, high mortality rates The methicillin-resistant staphylococcus aureus (MRSA) drugs market size is expected to see strong growth in the next few years. It will grow to " $3.03 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to continued antibiotic resistance challenges, advancements in MRSA diagnostics, global healthcare-associated infections, preventive measures in surgery, rising community-acquired MRSA cases. Major trends in the forecast period include exploration of immunomodulators, strategic partnerships for drug development, customized therapies based on strain characteristics, focus on pediatric-specific formulations, global health initiatives to combat antibiotic resistance. For further insights on this market, request a sample here

The methicillin-resistant staphylococcus aureus (mrsa) drugs market covered in this report is segmented –
1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users Subsegments:
1) By Lipopeptides: Daptomycin
2) By Oxazolidinones: Linezolid, Tedizolid
3) By Cephalosporin: Ceftaroline
4) By Tetracycline: Minocycline, Doxycycline
5) By Folate Antagonist: Trimethoprim Or Sulfamethoxazole
6) By Lipoglycopeptide: Telavancin, Dalbavancin, Oritavancin
7) By Other Drug Classes: Vancomycin, Clindamycin, Quinupristin Or Dalfopristin For further insights on this market, request a sample here

North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (MRSA) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the methicillin-resistant staphylococcus aureus (MRSA) drugs market include Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AmpliPhi Biosciences Corporation, AstraZeneca plc, Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc. . For further insights on this market, request a sample here.

Major trends in this market include Launch Of First Generic Version Of Combination Therapy For Helicobacter Pylori. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon